Details

Autor(en) / Beteiligte

• Dooley, Mary Anne
• Jayne, David
• Ginzler, Ellen M
• Isenberg, David
• Olsen, Nancy J
• Wofsy, David
• Eitner, Frank
• Appel, Gerald B
• Contreras, Gabriel
• Lisk, Laura
• Solomons, Neil

Titel

Mycophenolate versus Azathioprine as Maintenance Therapy for Lupus Nephritis

Ist Teil von

• The New England journal of medicine, 2011-11, Vol.365 (20), p.1886-1895

Ort / Verlag

Waltham, MA: Massachusetts Medical Society

Erscheinungsjahr

2011

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• In this double-blind, randomized trial, mycophenolate mofetil was superior to azathioprine for maintaining a renal response and preventing relapse in patients with lupus nephritis who had had a response to induction therapy. Systemic lupus erythematosus is an autoimmune disorder often characterized by the development of glomerulonephritis. 1 Renal involvement remains the strongest predictor of morbidity and mortality among patients with lupus, 1 and despite improvements in the management of lupus, the incidence of end-stage renal disease has not declined. 2 Management of lupus nephritis consists of induction therapy to achieve remission and long-term maintenance therapy to prevent relapse, progression to end-stage renal disease, and death. 3 However, the options for long-term therapy remain controversial. Treatment options include glucocorticoids and the immunosuppressive agents cyclophosphamide, azathioprine, and mycophenolate mofetil. These drugs have considerable toxicity and are not effective . . .